Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate

On Thursday, Sage Therapeutics Inc. (NASDAQ:SAGE) announced that Biogen Inc (NASDAQ:BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to the SAGE-324 program.

The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.

Essential tremor is a neurological disorder that causes involuntary shaking or trembling in certain body parts.

In July, the companies announced results from the ...